Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART

Inclusion Criteria:

- Male or female, 18 years of age or older with documented HIV diagnosis.

- Must be willing to comply with study-mandated evaluations; including discontinuation
of current antiretroviral therapy during the treatment interruption.

- Initiated HAART therapy within (≤) 1 year of HIV diagnosis or suspected infection.

- Undetectable HIV-1 RNA for at least 2 months prior to screening and at screening.

- CD4+ T-cell count ≥500 cells/µL.

- Absolute neutrophil count (ANC) ≥ 2500/mm3.

- Platelet count ≥ 200,000/mm3.

Exclusion Criteria:

- Acute or chronic hepatitis B or hepatitis C infection.

- Active or recent (in prior 6 months) AIDS defining complication.

- Any cancer or malignancy within the past 5 years, with the exception of successfully
treated basal cell or squamous cell carcinoma of the skin or low grade (0 or 1) anal
or cervical dysplasia.

- Current diagnosis of NYHA grade 3 or 4 CHF, uncontrolled angina or uncontrolled
arrhythmias.

- History or any features on physical examination indicative of a bleeding diathesis.

- Received HIV experimental vaccine within 6 months prior to screening, or any previous
gene therapy using an integrating vector.

- Use of chronic corticosteroids, hydroxyurea, or immunomodulating agents within 30
days prior to screening.

- Use of Aspirin, dipyridamole, warfarin or any other medication that is likely to
affect platelet function or other aspects of blood coagulation during the 2 week
period prior to leukapheresis.

- Currently participating in another clinical trial or participation in such a trial
within 30 days prior to screening visit.

- Currently taking maraviroc or have received maraviroc within 6 months prior to
screening.